Lilly Launches Citrate-Free Taltz® (Ixekizumab Injection) in China to Enhance Patient Experience
Eli Lilly
Global Pharmaceutical R&D and Production Company
Eli Lilly and Company Announces Launch of New Citrate-Free Formulation of Taltz®(Eli Lilly's ixekizumab injection), the concentration remains at 80 mg/mL. The new formulation received approval from the China National Medical Products Administration in November 2023 and contains the same active ingredient as the original formulation. Compared with the original formulation, Taltz...®The new formulation significantly reduced injection site pain for some patients, with an 86% reduction in the Visual Analogue Scale (VAS) score compared to the original formulation.iTaltz®Approved in 2019 for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and approved in 2022 for adult patients with active ankylosing spondylitis who have had an inadequate response to conventional therapy.
Taltz without citrate new formula®Demonstrates safety characteristics consistent with the original formulation product. Currently, the new formulation of Taltz®Are being transported across China, with an expected widespread availability for both new and existing patients by the end of May 2024.®Provided by the patient. During this period, the patient can still use the original Taltz formulation.®, until switching to the new citrate-free formulation of Taltz by Eli Lilly and Company.®. Existing Taltz®Patients do not need a new prescription and should not interrupt treatment due to the change between the old and new formulations.
An exciting milestone for nearly 10 million patients in China suffering from these autoimmune diseases.ii,iii, the significant impact of various symptoms of these diseases on patients' lives. Taltz formulation without citrate®The launch represents Eli Lilly's continued commitment to patient care, which will enhance the medication experience for patients.iv
Globally, more than 10,000 patients have participated in clinical trials for Taltz®, which has been launched in most global markets for over five years.vImproving the Use of Taltz by Providing a Novel Citrate-Free Formulation with the Same Active Ingredient®The experience of treated patients will bring benefits to more Chinese patients with moderate to severe plaque psoriasis and active ankylosing spondylitis. Through continuous innovation and enhancement of patient experience, Eli Lilly and Company will continue to fulfill its commitment to patient-centered research and investment.
References
i. Chabra S, et al. Adv Ther. 2022 Jun;39 (6) :2862-2872.
ii, Chinese Medical Association, Chinese Medical Association Publishing House, Chinese Medical Association Society of Dermatology and Venereology, et al. Psoriasis Primary Care Guidelines (2022) [J]. Chinese General Practitioners Magazine, 2022, 21(8): 705-714. DOI: 10.3760/cma.j.cn114798-20220214-00098.
iii. Huang Feng, et al. Diagnostic and Treatment Standards for Ankylosing Spondylitis. Chinese Journal of Internal Medicine, 2022, 61(8): 893-900.
iv. Sanjay Chabra, et al. EADV 2023. P0797.
v. Data on file. Lilly USA, LLC. DOF-IX-US-0310
Lilly
About Eli Lilly and Company
Eli Lilly and Company is a pharmaceutical company dedicated to improving human health through scientific innovation and benefiting patients worldwide. As a leader in the healthcare industry, Eli Lilly and Company has nearly 150 years of history. Today, our medicines have helped more than 51 million people globally. Harnessing the power of biotechnology, chemistry, and genomic medicine, our scientists are actively advancing new medical breakthroughs to address critical global health challenges. We are redefining therapies for diabetes and obesity, reducing the long-term impact of obesity on the body; supporting prevention and treatment efforts for Alzheimer’s disease; providing solutions for a range of immune-mediated diseases that threaten human health; and transforming difficult-to-treat cancers into manageable conditions. Every step Eli Lilly and Company takes toward a healthier world is driven by our belief in "making life better for millions of patients." This includes innovative clinical trials aimed at addressing multiple global challenges, while ensuring the accessibility and affordability of medicines. For more information about Eli Lilly and Company, please visit: www.lilly.com.
PP-IX-CN-4127